Cite this: Full-dose rivaroxaban for VTE in the elderly and those with CKD - Medscape - Jun 21, 2013. Authors and Disclosures. Authors and Disclosures ...

Methods: The ROCKET AF trial demonstrated the noninferiority of rivaroxaban (15 or 20 mg daily) compared with dose-adjusted warfarin (target international normalized ratio [INR] 2.0-3.0) for stroke ...

XARELTO® (rivaroxaban) is safe to use in elderly patients with nonvalvular atrial fibrillation, an analysis published in Circulation finds. The ROCKET AF trial looked at patients over age 75, ...

Kubitza, D, Becka, M, Roth, A, Mueck, W. Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. Curr Med Res Opin 2008;24:2757-2765 Crossref ...

According to the study, a primary efficacy outcome occurred in 17 of 1107 patients (1.5%) who were taking the 20 mg dose of rivaroxaban, and in 13 of the 1127 patients (1.2%) taking the 10 mg of ...

In the fall of 2018, the 2.5-mg dose of the name-brand rivaroxaban was introduced to the U.S., when it was approved for ...

However, compared with aspirin, rivaroxaban was associated with higher rates of major bleeding (risk difference, 0.9 percentage points; 95% CI, –0.1 to 3.7) and intracranial hemorrhage (risk ...

Rivaroxaban (Xarelto; Bayer/Janssen) given at a dose of 10 or 15 mg once daily significantly reduced thrombin generation in the first 10 days after the procedure compared with DAPT, Gilles Montalescot ...

In conclusion, this trial of thromboprophylaxis after total knee replacement found that rivaroxaban, an orally effective direct factor Xa inhibitor, given in a fixed, unmonitored, once-daily dose ...